Meta reported its Q1 earnings after the bell, beating analysts' expectations on the top and bottom, but a disappointing Q2 forecast sent shares falling.
Ever since college, Brad Jobling struggled with his weight, fluctuating between a low of 155 pounds when he was in his 30s to as high as 220. A little over a year ago, the 58-year-old Manhattan resident went on a new weight loss drug called Wegovy.
It follows the government's decision to scrap key climate targets and its response to a review into gender services.